EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The therapeutic impact of programmed death – 1 in the treatment of colorectal cancer

Pooria Salehi Sangani, Soroush Yazdani, Ghazaleh Khalili-Tanha, Elnaz Ghorbani, Ibrahim Saeed Al-Hayawi, Hamid Fiuji, Majid Khazaei, Seyed Mahdi Hassanian, MohammadAli Kiani, Majid Ghayour-Mobarhan, Gordon A Ferns, Elham Nazari und 1 weitere

Pathology - Research and Practice · 2024

DOI: 10.1016/j.prp.2024.155345 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pathology - Research and Practice, 2024. Verfasst von Pooria Salehi Sangani und 12 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Programmed Cell Death 1 Receptor, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 115 Literaturangaben. Gefördert von: Mashhad University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) is the most common type of newly diagnosed cancer. Metastatic spread and multifactorial chemoresistance have limited the benefits of current therapies. Hence, it is imperative to identify new therapeutic agents to increase treatment efficacy. One of CRC's most promising immunotherapeutic targets is programmed death-1 (PD-1), a cell surface receptor that regulates immune responses. In this paper, we provide an overview of the therapeutic impact of PD-1 in the treatment of CRC. Cancer cells can exploit the PD-1 pathway by upregulating its programmed death-ligand 1 (PD-L1) ligand to evade immune surveillance. The binding of PD-L1 to PD-1 inhibits T cell function, leading to tumor immune escape. PD-1 inhibitors, such as pembrolizumab and nivolumab, block the PD-1/PD-L1 interaction. Clinical trials evaluating PD-1 inhibitors in advanced CRC have shown promising results. In patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors characterized by high mutation rates and increased immunogenicity, PD-1 blockade has demonstrated remarkable efficacy. As a result, pembrolizumab and nivolumab have received accelerated approval by regulatory authorities for the treatment of MSI-H/dMMR metastatic CRC. Additionally, combination approaches, such as combining PD-1 inhibitors with other immunotherapies or targeted agents, are being explored. Despite the success of PD-1 inhibitors in CRC, challenges still exist. Immune-related adverse events can occur and require close monitoring. In conclusion, PD-1 inhibitors have demonstrated significant therapeutic impact, particularly in patients with MSI-H/dMMR tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsHumansB7-H1 AntigenImmunotherapyAntineoplastic Agents, ImmunologicalAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Anti-PD-L1Colorectal cancerCombination therapy

Substanzen

Programmed Cell Death 1 ReceptorImmune Checkpoint InhibitorsPDCD1 protein, humanB7-H1 AntigenpembrolizumabCD274 protein, humanAntineoplastic Agents, ImmunologicalAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq.
  • Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK.
  • Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: Elham.nazari@sbmu.ac.ir.

Förderung

  • Mashhad University of Medical Sciences

Zitieren

APA

Sangani, P. S., Yazdani, S., Khalili-Tanha, G., Ghorbani, E., Al-Hayawi, I. S., Fiuji, H., Khazaei, M., Hassanian, S. M., Kiani, M., Ghayour-Mobarhan, M., Ferns, G. A., Nazari, E., & Avan, A. (2024). The therapeutic impact of programmed death – 1 in the treatment of colorectal cancer. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2024.155345

Vancouver

Sangani PS, Yazdani S, Khalili-Tanha G, Ghorbani E, Al-Hayawi IS, Fiuji H, et al. The therapeutic impact of programmed death – 1 in the treatment of colorectal cancer. Pathology - Research and Practice. 2024. doi:10.1016/j.prp.2024.155345

BibTeX
@article{Sangani2024,
  author = {Sangani, Pooria Salehi and Yazdani, Soroush and Khalili-Tanha, Ghazaleh and Ghorbani, Elnaz and Al-Hayawi, Ibrahim Saeed and Fiuji, Hamid and Khazaei, Majid and Hassanian, Seyed Mahdi and Kiani, MohammadAli and Ghayour-Mobarhan, Majid and Ferns, Gordon A and Nazari, Elham and Avan, Amir},
  title = {The therapeutic impact of programmed death – 1 in the treatment of colorectal cancer},
  journal = {Pathology - Research and Practice},
  year = {2024},
  doi = {10.1016/j.prp.2024.155345}
}
Kostenlos starten →